US/EU Idiopathic pulmonary fibrosis drug sales "to rise 86.6%/year to 2017" PharmaTimes ... damage to the lung resulting from inflammation and scarring - has been overlooked by the healthcare industry until the last decade and, with no fully-effective therapies other than lung transplantation, very little is understood about its ... |
